BTTAY: AI 评分 48/100 — AI 分析 (4月 2026)

Biotest Aktiengesellschaft is a German biopharmaceutical company specializing in the development, manufacture, and sale of biological and biotechnological products. The company focuses on clinical immunology, haematology, and intensive care medicine, offering a range of therapies for various conditions.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

Biotest Aktiengesellschaft, a German biopharmaceutical company, develops and markets biological and biotechnological products, focusing on clinical immunology, haematology, and intensive care. With a global presence and a diverse product portfolio, Biotest addresses critical needs in specialized therapeutic areas, operating as a subsidiary of Grifols Biotest Holdings GmbH.

BTTAY是做什么的？

Biotest Aktiengesellschaft, founded in 1946 and headquartered in Dreieich, Germany, is a biopharmaceutical company specializing in biological and biotechnological pharmaceutical products. Originally named Biotest Serum-Institut GmbH, the company changed its name in 1986 to Biotest Aktiengesellschaft. The company focuses on the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its product portfolio includes treatments for haemophilia A and B, cytomegalovirus infection, hepatitis B, primary and secondary antibody deficiency syndromes, autoimmune diseases, varicella zoster virus infections, and hepatitis B reinfection following liver transplantation. Key products include Haemoctin SDH and Vihuma for haemophilia A, Haemonine for haemophilia B, Cytotect CP biotest for cytomegalovirus, Fovepta and Hepatect CP for hepatitis B, and Intratect and Yimmugo for antibody deficiency syndromes and autoimmune diseases. Additionally, Biotest offers Albiomin and Biseco for blood volume restoration, Cofact for coagulation factor deficiency, Fibrinogen for fibrinogen deficiency, Trimodulin for community-acquired pneumonia, and Pentaglobin for bacterial infections. Biotest has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin, expanding its global reach and market presence. As a subsidiary of Grifols Biotest Holdings GmbH, Biotest leverages its parent company's resources and expertise to further its research, development, and commercialization efforts.

BTTAY的投资论点是什么？

Biotest Aktiengesellschaft, with a market capitalization of $1.60 billion, presents a complex investment case. The company's focus on specialized therapeutic areas like immunology and haematology offers growth potential, particularly through its licensing agreement with Grifols. However, a negative profit margin of -3.9% and ROE of -4.7% raise concerns about profitability. The high debt-to-equity ratio of 131.22 indicates significant leverage. Upcoming catalysts include potential expansion of its product portfolio and increased market penetration through its partnership with Grifols. Potential risks include ongoing operational losses and the competitive nature of the biopharmaceutical industry.

BTTAY在哪个行业运营？

Biotest Aktiengesellschaft operates in the biopharmaceutical industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The global pharmaceuticals market is projected to reach trillions of dollars by 2026, driven by an aging population and increasing prevalence of chronic diseases. Biotest's focus on specialized therapeutic areas like immunology and haematology positions it within niche segments of this market. Competitors include major pharmaceutical companies and specialized biotech firms. The company's partnership with Grifols provides a competitive advantage through expanded market access and shared resources.

Pharmaceuticals

Healthcare

BTTAY有哪些增长机遇？

Expansion of Product Portfolio: Biotest has the opportunity to expand its product portfolio through internal research and development, as well as strategic acquisitions or licensing agreements. Focusing on innovative therapies in clinical immunology, haematology, and intensive care medicine can drive revenue growth. The global market for immunomodulatory drugs is projected to reach $124.7 billion by 2027, presenting a significant opportunity for Biotest. Timeline: Ongoing.
Increased Market Penetration through Grifols Partnership: The technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin provides Biotest with access to Grifols' global distribution network. This partnership can significantly increase market penetration and sales volume for these key products. The global market for plasma-derived therapies is expected to grow, driven by increasing demand for specialized treatments. Timeline: Ongoing.
Geographic Expansion: Biotest can pursue geographic expansion into new markets, particularly in emerging economies with growing healthcare expenditures. Expanding its presence in regions with unmet medical needs can drive revenue growth and diversify its revenue streams. The emerging markets pharmaceutical sector is expected to grow significantly, offering substantial opportunities for Biotest. Timeline: 3-5 years.
Strategic Acquisitions: Biotest could pursue strategic acquisitions of smaller biotechnology companies with complementary technologies or product pipelines. Acquiring innovative therapies or technologies can enhance Biotest's product portfolio and strengthen its competitive position. The market for mergers and acquisitions in the biopharmaceutical industry remains active, providing opportunities for strategic growth. Timeline: 2-3 years.
Development of Biosimilars: Biotest can invest in the development of biosimilars, which are follow-on versions of existing biologic drugs. Biosimilars offer a lower-cost alternative to branded biologics and can capture a significant share of the market. The global biosimilars market is projected to reach $35.7 billion by 2025, presenting a substantial opportunity for Biotest. Timeline: 5+ years.

Market Cap of $1.60B reflects Biotest's valuation in the biopharmaceutical sector.
Negative Profit Margin of -3.9% indicates ongoing challenges in achieving profitability.
Gross Margin of 23.2% suggests potential for improvement in production and sales efficiency.
Debt-to-Equity Ratio of 131.22 indicates a highly leveraged capital structure.
Free Cash Flow of $-0.00B reflects the company's current inability to generate positive cash flow.

BTTAY提供哪些产品和服务？

Develops biological pharmaceutical products.
Manufactures biological pharmaceutical products.
Sells biological pharmaceutical products in Germany and internationally.
Specializes in clinical immunology therapies.
Focuses on haematology treatments.
Provides intensive care medicine solutions.
Offers therapies for haemophilia A and B.
Develops treatments for autoimmune diseases.

BTTAY如何赚钱？

Develops and manufactures biological and biotechnological pharmaceutical products.
Sells products directly and through partnerships in Germany and internationally.
Generates revenue through the sale of specialized therapies for clinical immunology, haematology, and intensive care medicine.
Utilizes technology transfer and licensing agreements to expand market reach.

Hospitals and clinics requiring specialized therapies.
Patients with haemophilia A and B.
Individuals with cytomegalovirus infection.
Patients with hepatitis B.
Individuals with primary and secondary antibody deficiency syndromes.

Specialized product portfolio in niche therapeutic areas.
Technology transfer and licensing agreement with Grifols, S.A.
Established presence in the German biopharmaceutical market.
Expertise in developing and manufacturing biological pharmaceutical products.

什么因素可能推动BTTAY股价上涨？

Ongoing: Potential for increased revenue through the Grifols partnership.
Upcoming: Expansion of product portfolio through R&D initiatives.
Upcoming: Geographic expansion into emerging markets.
Ongoing: Development of new therapies for clinical immunology and haematology.

BTTAY的主要风险是什么？

Ongoing: Negative profit margin and ROE.
Ongoing: High debt-to-equity ratio.
Potential: Intense competition from major pharmaceutical companies.
Potential: Stringent regulatory requirements and approval processes.
Potential: Limited liquidity due to OTC market trading.

BTTAY的核心优势是什么？

Specialized product portfolio in immunology and haematology.
Established presence in Germany.
Partnership with Grifols for manufacturing and marketing.
Expertise in biological and biotechnological pharmaceutical products.

BTTAY的劣势是什么？

Negative profit margin and ROE.
High debt-to-equity ratio.
Dependence on a limited number of key products.
Limited geographic diversification.

BTTAY有哪些机遇？

Expansion of product portfolio through R&D and acquisitions.
Increased market penetration through Grifols partnership.
Geographic expansion into emerging markets.
Development of biosimilars.

BTTAY面临哪些威胁？

Intense competition from major pharmaceutical companies.
Stringent regulatory requirements and approval processes.
Risk of product liability claims.
Potential for generic erosion of key products.

BTTAY的竞争对手是谁？

Grifols, S.A. — Major player in plasma-derived therapies. — (GRFS)

Key Metrics

MoonshotScore: 48/100

Company Profile

Headquarters: Dreieich, Germany
Employees: 2,495

AI Insight

AI analysis pending for BTTAY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: BTTA

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Biotest Aktiengesellschaft do?

Biotest Aktiengesellschaft is a biopharmaceutical company that develops, manufactures, and sells biological and biotechnological pharmaceutical products. The company specializes in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its product portfolio includes therapies for haemophilia, cytomegalovirus infection, hepatitis B, antibody deficiency syndromes, autoimmune diseases, and bacterial infections. Biotest operates internationally and has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of certain products.

What do analysts say about BTTAY stock?

AI analysis is currently pending for BTTAY. Key valuation metrics to consider include the company's market capitalization of $1.60 billion, negative profit margin of -3.9%, and high debt-to-equity ratio of 131.22. Growth considerations include the potential for increased revenue through the Grifols partnership and expansion of the product portfolio. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.

What are the main risks for BTTAY?

The main risks for Biotest Aktiengesellschaft include its negative profit margin and ROE, high debt-to-equity ratio, intense competition from major pharmaceutical companies, stringent regulatory requirements, and limited liquidity due to its OTC market trading. The company's reliance on a limited number of key products also poses a risk, as generic erosion could impact revenue. Additionally, the OTC Other tier classification indicates a higher level of risk compared to companies listed on major exchanges.